Valion Bio (VBIO) Other Non Operating Income (2021 - 2022)
Valion Bio (VBIO) posted quarterly Other Non Operating Income of -$1000.0 for Q3 2022, down 101.25% year-over-year from $80000.0 in Q3 2021, and up 99.94% quarter-over-quarter from -$1.7 million in Q4 2021.
Valion Bio (VBIO) Other Non Operating Income (2021 - 2022) Analysis & Trends
Valion Bio's Other Non Operating Income history runs 2 years deep, the most recent figure standing at -$1000.0 for Q3 2022.
- In Q3 2022, Other Non Operating Income fell 101.25% year-over-year to -$1000.0; the TTM figure through Sep 2022 stood at -$1.5 million (changed N/A YoY), while the FY2021 annual figure was -$1.6 million, changed N/A from the prior year.
- Other Non Operating Income for Q3 2022 stood at -$1000.0, up from -$1.7 million in the prior quarter.
- The five-year high for Other Non Operating Income was $156000.0 in Q2 2021, with the low at -$1.7 million in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Valion Bio | 405,599.63 | -1.79 Mn | -45,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | -1,000.00 |
| Dec 31, 2021 | -1.72 Mn |
| Sep 30, 2021 | 80,000.00 |
| Jun 30, 2021 | 156,000.00 |
| Mar 31, 2021 | -27,000.00 |